Fermenta Biotech last traded at ₹518.80 (2026-10-13). Over the past month the stock moved +7.4%, three months the stock moved +75.7%, year the stock moved +54.0%. Its closing range over 52 weeks is ₹263.45 – ₹566.30, with the latest close 8.4% below the high.
Closing prices up to 2026-10-13.
Incorporated in 1951, Fermenta Biotech Ltd manufactures Active Pharmaceutical Ingredient, Aqua CHL, Biotechnology and Nutraceutical products[1]
Business Overview:[1][2] a) FBL is engaged in development and manufacturing of pharmaceuticals, biotechnology and environmental solutions used across various industries. It is a global player in manufacturing of Vitamin D3 in all its formats and has a non-China dependent supply chain. b) Company is involved in manufacturing of APIs for muscle relaxant and anti-flatulent applications. It delivers innovative enzymes used in manufacturing of active pharmaceutical ingredients and is involved in environmental solutions used for waste water treatment & management. c) Also, company has strategic investments in subsidiaries / associate companies primarily dealing in manufacturing and marketing bulk drugs and providing services of sporting and health awareness activities / education activities. d) Company also deals in lease rental business for ITES properties developed in Than
In the latest quarter (Jun 2026), Fermenta Biotech reported sales of ₹121.82 crore (-10.6%) and net profit of ₹9.53 crore (-55.9%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 121.82 | 18.06 | 14.83 | 9.53 | 3.31 |
| Mar 2026 | 121.58 | 20.00 | 16.45 | 18.60 | 6.52 |
| Dec 2025 | 137.36 | 24.96 | 18.17 | 12.02 | 4.31 |
| Sep 2025 | 130.22 | 26.64 | 20.46 | 18.03 | 6.14 |
| Jun 2025 | 136.26 | 28.24 | 20.73 | 21.60 | 7.42 |
| Mar 2025 | 139.85 | 36.95 | 26.42 | 33.32 | 11.68 |
| Dec 2024 | 156.47 | 53.27 | 34.04 | 37.89 | 12.54 |
| Sep 2024 | 95.03 | 18.78 | 19.76 | 11.12 | 3.87 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +67.0% | +58.1% | +43.7% | +74.4% | +37.0% | -12.2% | -13.1% | -10.6% |
| Operating profit growth | – | +112.0% | +586.8% | +3430.0% | +41.9% | -53.1% | -45.9% | -36.0% |
| Net profit growth | – | +279.3% | – | – | +62.1% | -68.3% | -44.2% | -55.9% |
| EPS growth | – | +274.3% | – | – | +58.7% | -65.6% | -44.2% | -55.4% |
| OPM % | 19.8% | 34.0% | 26.4% | 20.7% | 20.5% | 18.2% | 16.5% | 14.8% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
In the latest year (Mar 2026), Fermenta Biotech reported sales of ₹525.00 crore (+12.2%) and net profit of ₹70.00 crore (-7.9%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 525.00 | 100.00 | 19.00 | 70.00 | 24.39 |
| Mar 2025 | 468.00 | 115.00 | 25.00 | 76.00 | 26.12 |
| Mar 2024 | 335.00 | 28.00 | 8.00 | -24.00 | -7.84 |
| Mar 2023 | 349.00 | 18.00 | 5.00 | -53.00 | -17.36 |
| Mar 2022 | 397.00 | 62.00 | 16.00 | 15.00 | 5.25 |
| Mar 2021 | 376.00 | 83.00 | 22.00 | 43.00 | 15.46 |
| Mar 2020 | 292.00 | 66.00 | 23.00 | 60.00 | 20.23 |
| Mar 2019 | 403.00 | 156.00 | 39.00 | 117.00 | 42.71 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +33.4% | -27.5% | +28.8% | +5.6% | -12.1% | -4.0% | +39.7% | +12.2% |
| Operating profit growth | +67.7% | -57.7% | +25.8% | -25.3% | -71.0% | +55.6% | +310.7% | -13.0% |
| Net profit growth | +154.3% | -48.7% | -28.3% | -65.1% | -453.3% | – | – | -7.9% |
| EPS growth | +249.8% | -52.6% | -23.6% | -66.0% | -430.7% | – | – | -6.6% |
| OPM % | 39.0% | 23.0% | 22.0% | 16.0% | 5.0% | 8.0% | 25.0% | 19.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
No AI analysis generated yet for Fermenta Biotech.
Get Free AI Stock Analysis FREE →Fermenta Biotech inks pact with VIT for Vitamin B12 Fortification Technology
Fermenta Biotech shines on inking pact with VIT for Vitamin B12 Fortification Technology
Fermenta Biotech shares were last quoted at ₹518.80 (+0.2% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
Fermenta Biotech has a price-to-earnings (P/E) ratio of 22.78 and a price-to-book (P/B) ratio of 3.31. The industry P/E is 53.33.
The 52-week high of Fermenta Biotech is ₹579.65 and the 52-week low is ₹256.40.
The market capitalisation of Fermenta Biotech is about ₹1,377.81 crore.
In the latest quarter (Jun 2026), Fermenta Biotech reported sales of ₹121.82 crore (-10.6%) and net profit of ₹9.53 crore (-55.9%), compared with the same quarter last year.
Promoters hold about 64.08% of Fermenta Biotech.
Fermenta Biotech belongs to the Pharmaceuticals & Drugs sector.